Are Obese Individuals with no Feature of Metabolic Syndrome but Increased Waist Circumference Really Healthy? A Cross Sectional Study

Abstract

Aim: Patients displaying the metabolically healthy but obese phenotype have an intermediate cardiometabolic prognosis compared to normal weight healthy and metabolically unhealthy obese subjects. We aimed to evaluate the proportion of patients with a definite metabolically healthy obese phenotype and better characterize them.

Methods: Definite metabolically healthy obese phenotype was defined as having none of the International Diabetes Federation metabolic syndrome criteria, excluding waist circumference. We recruited 1 159 obese patients (body mass index 38.4±6.3 kg/m²) including 943 women, without known diabetes. Patients were characterized for cardiometabolic disorders.

Results: As the 202 (17.4%) metabolically healthy obese individuals were younger and had lower body mass indexes than the 957 metabolically unhealthy obese patients, they were matched for gender, age and body mass index with 404 metabolically unhealthy obese patients. In addition to the features of metabolic syndrome, when compared to unhealthy subjects, definite metabolically healthy obese patients were less frequently found with either homeostasis model assessment of insulin resistance index>3 (23.6 vs. 38.9%, p<0.001), or abnormal oral glucose tolerance test (13.9 vs. 33.9%, p<0.001), or HbA1c value≥5.7% (43.9 vs. 54.2%, p<0.05) or pulse pressure≥60 mmHg (11.7 vs. 64.9%, p<0.001). However, there were no significant differences in the prevalence of microalbuminuria (11.1 vs. 12.3%), cardiac autonomic dysfunction (45.5 vs. 35.3%) and fatty liver index ≥ 60 (5.6 vs. 10.2%).

Conclusion: Our data do not support the characterization of metabolically healthy obesity, even definite, as really healthy, as many patients with this phenotype have abnormal cardiovascular markers and glucose or liver abnormalities. HbA1c measurement seems to be more sensitive than OGTT to detect dysglycemia in this population.

Key words

metabolically healthy obesity - arterial stiffness - cardiac autonomic dysfunction - fatty liver index - oral glucose tolerance test - microalbuminuria

^* SC and EC contributed equally to this work

• References

• 1 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl. 01) S81-S90
• 2 Appleton SL, Seaborn CJ, Visvanathan R et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013; 36: 2388-2394
• 3 Arnlov J, Ingelsson E, Sundstrom J et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236
• 4 Aung K, Lorenzo C, Hinojosa M et al. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab 2014; 99: 462-468
• 5 Ayad F, Belhad M, Paries J et al. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med 2010; 27: 804-811
• 6 Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
• 7 Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997
• 8 Camhi SM, Katzmarzyk PT. Differences in body composition between metabolically healthy obese and metabolically abnormal obese adults. Int J Obes (Lond) 2013; [Epub ahead of print]
• 9 Cosson E, Hamo-Tchatchouang E, Banu I et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab 2010; 36: 312-318
• 10 Cosson E, Pham I, Valensi P et al. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 2006; 29: 107-112
• 11 DECODE Study Group tEDEG. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
• 12 Durward CM, Hartman TJ, Nickols-Richardson SM. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. J Obes 2012; 2012: 460321
• 13 Hinnouho GM, Czernichow S, Dugravot A et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter?. Diabetes Care 2013; 36: 2294-2300
• 14 Hinnouho GM, Czernichow S, Dugravot A et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J 2015; 36: 551-559 [pii] 10.1093/eurheartj/ehu123
• 15 Hong HC, Lee JS, Choi HY et al. Liver enzymes and vitamin D levels in metabolically healthy but obese individuals: Korean National Health and Nutrition Examination Survey. Metabolism 2013; 62: 1305-1312
• 16 Kelly R, Hayward C, Avolio A et al. Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989; 80: 1652-1659
• 17 Kramer CK, Zinman B, Retnakaran R. Are Metabolically Healthy Overweight and Obesity Benign Conditions?: A Systematic Review and Meta-analysis. Ann Intern Med 2013; 159: 758-769
• 18 Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality?. Diabetes Care 2009; 32: 2297-2299
• 19 Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912
• 20 Messier V, Karelis AD, Robillard ME et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism 2010; 59: 20-24
• 21 National Cholesterol Education Program (NCEP) Expert Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
• 22 Oni ET, Agatston AS, Blaha MJ et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013; 230: 258-267
• 23 Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14: 219-227
• 24 Robles NR, Felix FJ, Fernandez-Berges D et al. Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study. Eur J Clin Invest 2012; 42: 1272-1277
• 25 Samaropoulos XF, Hairston KG, Anderson A et al. A metabolically healthy obese phenotype in hispanic participants in the IRAS family study. Obesity (Silver Spring) 2013; 21: 2303-2309
• 26 Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-653
• 27 Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
• 28 Valensi P, Assayag M, Busby M et al. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996; 20: 574-579
• 29 Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 2013; 56: 1196-1200
• 30 Valensi P, Thi BN, Lormeau B et al. Cardiac autonomic function in obese patients. Int J Obes Relat Metab Disord 1995; 19: 113-118
• 31 Weghuber D, Zelzer S, Stelzer I et al. High risk vs. “metabolically healthy” phenotype in juvenile obesity – neck subcutaneous adipose tissue and serum uric acid are clinically relevant. Exp Clin Endocrinol Diabetes 2013; 121: 384-390
• 32 Wildman RP, Muntner P, Reynolds K et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008; 168: 1617-1624